| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
Factor B is a zymogen that carries the catalytic site of the
complement alternative pathway convertases. During C3 convertase
assembly, factor B associates with C3b and is cleaved at a single site
by factor D. The Ba fragment is released, leaving the active complex,
C3bBb. During the course of this process, the protease domain becomes
activated. The type A domain of factor B, also part of Bb, is similar
in structure to the type A domain of the complement receptor and
integrin, CR3. Previously, mutations in the factor B type A domain were
described that impair C3b-binding. This report describes "gain of
function" mutations obtained by substituting factor B type A domain
amino acids with homologous ones derived from the type A domain of CR3.
Replacement of the ßA-
1 Mg2+ binding loop residue D254
with smaller amino acids, especially glycine, increased hemolytic
activity and C3bBb stability. The removal of the oligosaccharide at
position 260, near the Mg2+ binding cleft, when combined
with the D254G substitution, resulted in increased affinity for C3b and
iC3b, a C3b derivative. These findings offer strong evidence for the
direct involvement of the type A domain in C3b binding, and are
suggestive that steric effects of the D254 sidechain and the
N260-linked oligosaccharide may contribute to the regulation of ligand
binding.
This article has been cited by other articles:
|
|
 |
|
  E. Torreira, A. Tortajada, T. Montes, S. Rodriguez de Cordoba, and O. Llorca Coexistence of Closed and Open Conformations of Complement Factor B in the Alternative Pathway C3bB(Mg2+) Proconvertase J. Immunol., December 1, 2009; 183(11): 7347 - 7351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Roumenina, M. Jablonski, C. Hue, J. Blouin, J. D. Dimitrov, M.-A. Dragon-Durey, M. Cayla, W. H. Fridman, M.-A. Macher, D. Ribes, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome Blood, September 24, 2009; 114(13): 2837 - 2845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Torreira, A. Tortajada, T. Montes, S. R. de Cordoba, and O. Llorca 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase PNAS, January 20, 2009; 106(3): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. de Jorge, C. L. Harris, J. Esparza-Gordillo, L. Carreras, E. A. Arranz, C. A. Garrido, M. Lopez-Trascasa, P. Sanchez-Corral, B. P. Morgan, and S. R. de Cordoba Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome PNAS, January 2, 2007; 104(1): 240 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kuttner-Kondo, M. P. Dybvig, L. M. Mitchell, N. Muqim, J. P. Atkinson, M. E. Medof, and D. E. Hourcade A Corresponding Tyrosine Residue in the C2/Factor B Type A Domain Is a Hot Spot in the Decay Acceleration of the Complement C3 Convertases J. Biol. Chem., December 26, 2003; 278(52): 52386 - 52391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hourcade, L. Mitchell, L. A. Kuttner-Kondo, J. P. Atkinson, and M. E. Medof Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) via Sites on the Type A Domain of Bb J. Biol. Chem., January 4, 2002; 277(2): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, M. Ma, G. C. Ippolito, H. W. Schroeder Jr., M. C. Carroll, and J. E. Volanakis Complement activation in factor D-deficient mice PNAS, December 4, 2001; 98(25): 14577 - 14582. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
